Pancreatic Cancer Research

ResearcherNational and Kapodistrian University of AthensActive in the last 2 years

Evangelos Koustas

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0583-0540; OpenAlex author ID A5040334266. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2020: 3 papers · 2021: 2 papers · 2022: 2 papers · 2023: none · 2024: 2 papers

Papers 9

  1. l-Securinine Induces ROS-Dependent Apoptosis on Pancreatic Cancer Cells via the PI3K/AKT/mTOR Signaling Pathway. Co-author DOI 10.1002/jbt.70036↗
  2. A Current Synopsis of the Emerging Role of Extracellular Vesicles and Micro-RNAs in Pancreatic Cancer: A Forward-Looking Plan for Diagnosis and Treatment. Co-author DOI 10.3390/ijms25063406↗
  3. Targeting the Endocannabinoid System: From the Need for New Therapies to the Development of a Promising Strategy. What About Pancreatic Cancer? Co-author DOI 10.21873/invivo.12736↗
  4. The Emerging Role of MicroRNAs and Autophagy Mechanism in Pancreatic Cancer Progression: Future Therapeutic Approaches. Co-author DOI 10.3390/genes13101868↗
  5. Combinatorial Treatment of Tinzaparin and Chemotherapy can Induce a Significant Antitumor Effectin Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-551892/v1↗
  6. Combinatorial Treatment of Tinzaparin and Chemotherapy Can Induce a Significant Antitumor Effect in Pancreatic Cancer. Co-author DOI 10.3390/ijms22137053↗
  7. Immunotherapy for pancreatic cancer: A 2020 update. Co-author DOI 10.1016/j.ctrv.2020.102016↗
  8. Pancreatic Cancer and Cachexia-Metabolic Mechanisms and Novel Insights. Co-author DOI 10.3390/nu12061543↗
  9. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. First author DOI 10.4251/wjgo.v12.i2.173↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Panagiotis Sarantis · 8 shared papers, 2020–2024 · strength 1.19
  2. Michalis V. Karamouzis · 7 shared papers, 2020–2024 · strength 0.99
  3. Athanasios G. Papavassiliou · 4 shared papers, 2020–2021 · strength 0.52
  4. Dimitriοs Schizas · 3 shared papers, 2020–2021 · strength 0.36
  5. Eleni-Myrto Trifylli · 2 shared papers, 2022–2024 · strength 0.34
  6. Nikolaos Garmpis · 2 shared papers, 2022 · strength 0.27
  7. Christos Damaskos · 2 shared papers, 2022 · strength 0.27
  8. Pavlos Papakotoulas · 2 shared papers, 2021 · strength 0.25
  9. Stamatios E Theocharis · 2 shared papers, 2021 · strength 0.25
  10. Evangelos S. Felekouras · 2 shared papers, 2021 · strength 0.25
  11. Alexandros Papalampros · 2 shared papers, 2021 · strength 0.25
  12. Ioanna A. Anastasiou · 1 shared paper, 2024 · strength 0.21
  13. Nikolaοs Tentolouris · 1 shared paper, 2024 · strength 0.21
  14. Melanie J. Deutsch · 1 shared paper, 2024 · strength 0.19
  15. Kalliopi‐Anna Poulia · 1 shared paper, 2020 · strength 0.13
  16. Efstathios Antoniou · 1 shared paper, 2022 · strength 0.12
  17. Gregory P. Kouraklis · 1 shared paper, 2022 · strength 0.12
  18. Dimitrios C. Ziogas · 1 shared paper, 2020 · strength 0.11
  19. Christo Kole · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.